Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Assets: 2021-2024

Historic Other Non-Current Assets for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $231,000.

  • Krystal Biotech's Other Non-Current Assets rose 64.04% to $333,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $333,000, marking a year-over-year increase of 64.04%. This contributed to the annual value of $231,000 for FY2024, which is 12.17% down from last year.
  • Krystal Biotech's Other Non-Current Assets amounted to $231,000 in FY2024, which was down 12.17% from $263,000 recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Other Non-Current Assets registered a high of $324,000 during FY2022, and its lowest value of $74,000 during FY2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $263,000 (2023), whereas its average is $272,667.
  • As far as peak fluctuations go, Krystal Biotech's Other Non-Current Assets skyrocketed by 337.84% in 2022, and later declined by 18.83% in 2023.
  • Over the past 4 years, Krystal Biotech's Other Non-Current Assets (Yearly) stood at $74,000 in 2021, then soared by 337.84% to $324,000 in 2022, then dropped by 18.83% to $263,000 in 2023, then fell by 12.17% to $231,000 in 2024.